ADAM17 and type 2 diabetes mellitus: This study suggested that in patients with type 2 diabetes, the deregulation of ADAM17 and MMP9 activities in atherosclerotic plaques is associated with an impaired expression of TIMP3 via SIRT1 (Cardellini et al., 2009).